EMA Authorised: Myfenax (mycophenolate mofetil) — Teva B.V.

View source ↗

Summary

The European Medicines Agency authorised Myfenax, a generic mycophenolate mofetil product by Teva B.V., for preventing graft rejection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft Rejection

Drugs mentioned

• Myfenax (mycophenolate mofetil)

Snippet

Status: Authorised. Therapeutic area: Graft Rejection. MAH: Teva B.V.. Decision date: 26/03/2026